Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of 3 different dose levels of CLR 125 in patients with advanced triple negative breast cancer. The main questions the study aims to answer are: What dose and regimen should be used in future trials of CLR 125 in patients with advanced triple negative breast cancer. What side effects do participants have when taking CLR 125. Participants will: Have CLR 125 administered via infusion 4 times each cycle; repeated every 8 weeks. Visit the clinic once every 3 weeks for checkups and testing.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Breast Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cellectar Biosciences, Inc.
- Last updated on ClinicalTrials.gov
- October 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Mayo Clinic Florida · Jacksonville, FL
Maryland · 1
- United Theranostics · Glen Burnie, MD
Minnesota · 1
- Mayo Clinic Rochester · Rochester, MN
New Jersey · 1
- United Theranostics · Princeton, NJ
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.